on behalf of the C-EDGE IBLD Study Investigators Direct-acting antiviral agents have not been studied exclusively in patients with inherited blood disorders and hepatitis C virus (HCV) infection. The objective of the randomized, placebo-controlled, phase III C-EDGE IBLD study was to assess the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) in patients with inherited bleeding disorders and HCV infection. One hundred fifty-nine adults with HCV infection and sickle cell anemia, thalassemia, or hemophilia A/B or von Willebrand disease were enrolled at 31 study sites in the United States, Europe, Australia, Canada, Israel, and Thailand. Patients were given an oral, once-daily, fixed-dose combination of EBR/GZR 50 mg/100 mg for 12 weeks and randomized to the immediate-treatment group (ITG) or deferred-treatment group (DTG; placebo followed by active treatment). The primary endpoints were the proportion of patients in the ITG with unquantifiable HCV RNA 12 weeks posttreatment (sustained virological response 12 weeks after completion of study treatment; SVR12) and the comparison of safety in the ITG and DTG. In the ITG, 100 of 107 patients (93.5%) achieved SVR12, 6 relapsed, and 1 was lost to follow-up. SVR12 was achieved in 94.7% (18 of 19), 97.6% (40 of 41), and 89.4% (42 of 47) of patients with sickle cell disease, b-thalassemia, and hemophilia A/B or von Willebrand disease, respectively. Serious adverse events were reported by 2.8% (n 5 3) and 11.5% (n 5 6) of patients in the ITG and DTG, respectively. Hemoglobin levels and international normalized ratio values were similar in patients receiving EBR/GZR and placebo; among patients with hemoglobinopathies, change in mean hemoglobin levels was similar in those receiving EBR/GZR compared to those receiving placebo. Conclusion: These results add to the expanding pool of data available for EBR/GZR, indicating a high level of efficacy and favorable tolerability in patients with HCV infection. (HEPATOLOGY 2017;66:736-745) 
B efore effective and universal screening of blood and blood-derived clotting factors, almost all patients with inherited blood disorders (IBLDs), including those with hemoglobinopathies such as sickle cell disease and b-thalassemia or clotting factor deficiencies such as hemophilia and von Willebrand disease, were also infected with the hepatitis C virus (HCV). (1) Patients with IBLDs are living longer attributable to improvements in their specialized medical care, but remain at risk for the significant morbidity and mortality (such as end-stage liver disease and hepatocellular carcinoma) associated with HCV infection. (2) While improvements in blood banking procedures have led to almost no transfusion-associated HCV infections in Western countries, HCV-contaminated blood products continue to contribute new cases of HCV infection in resource-constrained settings. (3) Frequent comorbidities in patients with IBLDs complicate HCV treatment with interferon (IFN) and ribavirin (RBV), the standard of care for HCV treatment before the introduction of direct-acting antiviral (DAA) agents in 2011. (3) Although the standard of care for management of chronic HCV infection has evolved to tolerable and efficacious IFN-free combinations of DAA agents for a majority of individuals with chronic HCV infection, (4, 5) these therapies have not been studied extensively in patients with IBLD, particularly in those with hemolytic anemias, and DAA agent treatment regimens still include coadministration of RBV for certain patient subgroups. Clinical data for these new regimens in patients with IBLDs are limited to a small single-arm study of ledipasvir/sofosbuvir plus RBV in individuals with inherited clotting factor disorders. (6) The combination of elbasvir (EBR), a once-daily nonstructural (NS) 5A inhibitor, and grazoprevir, (GZR), a once-daily HCV NS3/4A protease inhibitor, has been approved by the U.S. Food and Drug Administration for the treatment of patients with HCV genotype (GT) 1 or 4 infection. (7) This combination therapy has potent antiviral activity in vitro (8, 9) and high efficacy across a wide spectrum of patients with HCV infection in phase II and III clinical trials, including patients with cirrhosis, chronic kidney disease (CKD), human immunodeficiency virus (HIV) coinfection, and/or previous failure to IFN-based therapy. (10) (11) (12) (13) (14) (15) (16) Rates of sustained virological response (SVR) above 90% have been achieved in phase III studies when administered for 12 weeks without RBV, and placebocontrolled comparisons suggest a safety profile that did not differ markedly from placebo. (12) Herein, we report data from C-EDGE IBLD (ClinicalTrials.gov: NCT02252016), which evaluates an RBVfree DAA agent regimen in a cohort of patients with hemoglobinopathies, including patients with hemolytic anemias, in whom RBV may exacerbate anemia and potentially worsen the clinical complications from transfusion-associated iron overload. The aim of this randomized, phase III study was to assess the safety and efficacy of EBR/GZR in patients with sickle cell disease, thalassemia, or hemophilia/von Willebrand disease and HCV infection. A randomized placebo treatment arm (placebo followed by deferred active treatment with EBR/GZR) was included in this study to provide a comparative assessment of the safety profile of EBR/GZR in this patient population with frequent comorbidities.
Patients and Methods
Male and female adult patients with HCV GT1, 4, or 6 infection (HCV RNA 10 000 IU/mL in peripheral blood) and sickle cell disease, b-thalassemia, or hemophilia A/B or von Willebrand disease were enrolled. Patients with and without compensated cirrhosis were eligible for enrollment. Cirrhosis was defined on biopsy before day 1 of enrollment or by FibroScan showing >12.5 kilopascals performed within 12 months of enrollment, or a combination of a FibroTest score >0.75 and an alanine aminotransferase (AST)/platelet ratio index > 2. Patients were either na€ ıve to previous HCV treatment, had previously received IFN or pegylated IFN (Peg-IFN)-based antiviral therapy, or were intolerant to Peg-IFN/RBV. A diagnosis of sickle cell disease was based on electrophoretic or highperformance liquid chromatography documentation of the hemoglobin S-only phenotype. Patients with bthalassemia were required to have an established diagnosis of thalassemia major (based on electrophoresis or a clinical diagnosis), and patients with hemophilia A/B or von Willebrand disease had a documented reduction in von Willebrand factor with or without factor VIII deficiency. Patients with sickle cell disease or b-thalassemia were required to have hemoglobin levels >7.0 g/dL. Patients with HIV/HCV coinfection were enrolled, provided they were receiving stable antiretroviral therapy using tenofovir or abacavir and either emtricitabine or lamivudine plus raltegravir, dolutegravir, or rilpivirine for 8 weeks before study entry and had a CD4 Patients were excluded from the study if they had evidence of decompensated liver disease, were coinfected with hepatitis B virus, had a clinical diagnosis of substance abuse, or had a history of malignancy. Patients with sickle cell disease with acute pain crisis requiring intravenous analgesics within the previous month, with a vaso-occlusive pain episode lasting longer than 2 weeks or > 12 pain episodes during the preceding year, were also excluded (see the Supporting Information for laboratory exclusion criteria).
STUDY DESIGN AND CONDUCT
The study was conducted in accord with the provisions of the Declaration of Helsinki, the International Conference on Harmonization guidelines, and other regulations governing clinical study conduct. The protocol was approved by an independent ethics committee or institutional review board at each participating site (Protocol PN065; Supporting Information). All patients provided written informed consent.
Patients were randomized in a 2:1 ratio to immediate or deferred treatment. Patients randomized to the immediate-treatment group (ITG) received EBR/GZR 50 mg/100 mg for 12 weeks as single-entity tablets. Patients randomized to the deferred-treatment group (DTG) received 12 weeks of placebo (consisting of singleentity placebo tablets for EBR and GZR) followed by a 4-week follow-up period and then EBR/GZR for 12 weeks administered as a fixed-dose combination tablet. Randomization was performed centrally using an interactive voice response system/integrated web response system with stratification according to fibrosis stage (cirrhotic vs. noncirrhotic) and disease (sickle cell disease vs. b-thalassemia vs. hemophilia/von Willebrand disease). EBR/GZR and placebo were packaged identically so that masking was maintained. Patients, investigators, and all site personnel were unaware of treatment assignment. All patients were followed for 24 weeks following completion of study therapy.
ENDPOINTS
The primary endpoints were SVR 12 weeks after the completion of all study treatment (SVR12; HCV RNA undetectable [<15 IU/mL] or detectable but unquantifiable [<lower limit of quantitation {LLoQ} 15 IU/mL]) in the ITG and the safety and tolerability of EBR/GZR in the ITG relative to placebo treatment in the DTG. A secondary efficacy endpoint was SVR 24 weeks after completion of treatment within the ITG. SVR12 data from the deferred EBR/GZR treatment of patients who initially received placebo will be reported elsewhere. Exploratory endpoints included the impact of baseline resistance-associated substitutions (RASs) on efficacy. In addition, emergence of RASs was assessed in patients who met criteria for virological failure with HCV RNA >1,000 IU/mL. Virological failure was defined as nonresponse (detectable HCV RNA at end of treatment without HCV RNA <LLoQ on treatment); rebound (>1 log 10 IU/ mL increase in HCV RNA from nadir while on treatment); breakthrough (HCV RNA LLoQ on treatment after previously having HCV RNA <LLoQ); or relapse (HCV RNA undetectable at end of treatment, then HCV RNA LLoQ during follow-up). Safety was assessed by the monitoring of adverse events 
ASSESSMENTS
Blood samples for assessment of HCV RNA were collected at baseline, at treatment weeks 1, 2, 3, 4, 6, 8, 10, and 12 (end of treatment), and at follow-up weeks 4, 8, 12, and 24. Plasma HCV-RNA levels were measured using Roche cobas Ampliprep/cobas Taqman HCV test version 2.0 (Roche Molecular Diagnostics, Branchburg, NJ) with an LLoQ of <15 IU/mL. Blood samples for assessment of viral resistance were collected at baseline for all patients and at virological failure for any patient who met criteria for virological failure and with HCV RNA >1,000 IU/mL. The specific loci evaluated for GT1 NS5A RASs were any polymorphism at amino acid positions 28, 30, 31, and 93, whereas positions 24 and 58 were evaluated for GT4 and 6 samples. The specific loci for NS3 RASs were any polymorphism at amino acid positions 36, 54, 55, 56, 80, 107, 122, 132, 155, 156, 158, 168, 170, and 175. HCV RNA from blood samples with HCV-RNA levels of 1,000 IU/mL was reverse-transcribed and amplified using RT-PCR followed by population sequencing of the NS5A and NS3 genes. The limit of minority variant detection in the population was >25% of the viral population.
STATISTICAL ANALYSIS
Target enrollment was to randomize approximately 134 patients into the ITG and 67 patients into the DTG. Assuming a response rate of 70% in the ITG, the study has over 99% power to demonstrate that SVR12 is superior to a reference rate of 40% at an overall one-sided 2.5% alpha level. Because no significant large clinical trial has enrolled patients with IBLDs, the historical reference rate was derived from the IDEAL phase III study of Peg-IFN plus RBV in patients with HCV GT1 infection without IBLD. (17) This hypothesis was evaluated in patients from the ITG and tested at a one-sided significance level (type 1 error) of 0.025. A two-sided 95% confidence interval (CI) was also constructed for the SVR12 rate.
The primary efficacy analysis was evaluated in the full analysis set population, which consists of all randomized patients who received at least one dose of study medication. The modified full analysis set includes all patients from the full analysis set, but excludes those with HCV GT2, 3, or 5 infection at baseline. Safety analyses were conducted in the "all subjects as treated" population, which consists of all randomized patients who received 1 dose of study medication.
Results

PATIENT DISPOSITION
A total of 186 patients were screened and 159 patients were randomized across 31 study sites in the United States, Europe, Australia, Canada, Israel, and Thailand. The first patient received their first dose of therapy on November 17, 2014, and the final patient completed 12 weeks of follow-up on March 24, 2016. Of the 27 patients who were screened but not randomized, 2 were
lost to follow-up, 1 withdrew, and 24 failed to meet inclusion/exclusion criteria. In total, 107 patients were randomized to immediate treatment with EBR/GZR and 52 were randomized to the DTG (Fig. 1) . Most patients were white (76%) and male (75%), with GT1 infection (88%; Table 1 ). There were no patients with mixed HCV infections. In the ITG, 24% were patients with cirrhosis, 6% had HIV coinfection, 64% had baseline viral load >800,000 IU/mL, and approximately half had failed prior IFN-based therapy. Eighteen percent of patients (19 of 107) had sickle cell disease, 38% (41 of 107) had b-thalassemia, and 44% (47 of 107) had hemophilia A/B or von Willebrand disease.
One patient in the ITG discontinued treatment early because of noncompliance with study medication and did not participate further in the study. The final HCV-RNA assessment for this patient was undetectable HCV RNA at treatment week 8. Two patients receiving placebo in the DTG failed to complete the initial 12-week placebo period (AE, n 5 1; withdrawal by patient, n 5 1).
VIROLOGICAL RESPONSE
In the ITG full analysis set population, 100 of 107 patients (93.5%) achieved SVR12 ( Table 2 ). During treatment, 43.0% (46 of 107) of patients had undetectable HCV RNA (<15 IU/mL) by week 2 of therapy, 84.1% (90 of 107) by week 4, and all (100.0%) after completing 12 weeks of treatment. Of the 7 patients who did not achieve SVR12, 6 relapsed and 1 was lost to follow-up after having undetectable HCV RNA at end of treatment. In the modified full analysis set, which excluded the patient who was lost to follow-up, SVR was achieved by 100 of 106 patients (94.3%).
SVR12 was high across the major patient subgroups (Fig. 2) . SVR12 was 91.5% (43 of 47), 95.7% (44 of 46), Abbreviations: BMI, body mass index; IL28B, interleukin-28B; NA, not available. (Fig. 3) . All 4 patients with baseline NS5A RASs also had baseline NS3 RASs. SVR12 was 25.0% (1 of 4) in those with baseline NS5A RASs and 97.6% (42 of 43) in those with no baseline NS5A RASs. The patient with an NS5A RAS present at baseline who achieved SVR12 had a baseline Q30H RAS, which causes a 6-fold reduction in the potency of EBR in vitro. In contrast, 55.3% (26 of 47) of patients with GT1a infection had baseline NS3 RASs. Rates of SVR12 were 88.5% (23 of 26) and 95.2% (20 of 21) in GT1a-infected patients with 
and without baseline NS3 RASs. Of the 26 patients with baseline NS3 RASs, 22 had only NS3 RASs (i.e., no NS5A RASs), all of whom achieved SVR12. One patient had an NS3 RAS at baseline that causes a >5-fold reduction in grazoprevir potency in vitro: this patient had baseline R168E and also achieved SVR12. All patients with NS3 RASs who failed treatment also had NS5A RASs at baseline. Six patients relapsed; 5 had HCV GT1 infection (GT1a, n 5 4; GT1b, n 5 1) and 1 had GT4 infection (see the Supporting Information for more details about the patients). Five of 6 patients had NS5A and NS3 RASs present at baseline and all 6 had NS5A and NS3 RASs at time of failure. At failure, 4 relapsers had NS5A variants at amino acid residue 30, 4 had variants at amino acid position 93, 3 had variants at amino acid residue 31, and 2 had variants at amino acid residue 28.
AEs
The safety profile was similar in patients receiving EBR/GZR versus those receiving placebo. The most frequent AEs among patients in the ITG were headache, fatigue, nausea, and asthenia (Table 3) . Serious AEs were reported by 3 (2.8%) patients in the ITG (1 patient with b-thalassemia and erosive gastritis and hypophosphatemia, 1 with sickle cell disease with crisis, and 1 with hemophilia A and rectal hemorrhage), and 6 (11.5%) receiving placebo (sickle cell disease with crisis, sickle cell disease with crisis and anemia, fall, increased alanine aminotransferase [ALT]/AST, osteonecrosis, and chronic myeloid leukemia). In the ITG group, only the serious AE of erosive gastritis with hypophosphatemia was considered to be drug related. Five serious AEs were reported as related to the underlying blood disorder: 2 in patients receiving EBR/GZR (sickle cell disease with crisis and rectal hemorrhage) and 3 in those receiving placebo in the DTG (sickle cell disease with crisis, n 5 2; anemia, n 5 1). There were no discontinuations attributed to safety events among patients receiving EBR/GZR. One patient receiving placebo met the protocol-specified criteria for treatment discontinuation because of an AE of increased ALT and AST. Laboratory assessments of hemoglobin and clotting parameters were similar in both the ITG and DTG. For the duration of treatment, hemoglobin levels and international normalized ratio (INR) values were similar in patients receiving EBR/GZR and placebo (Table  3) . Among patients with hemoglobinopathies (sickle cell disease and b-thalassemia), the on-treatment change in mean hemoglobin levels was also similar in patients receiving EBR/GZR compared with those receiving placebo (see the Supporting Information for details). Approximately 40% of patients in both treatment arms had nadir hemoglobin levels <9.0 g/dL. Eight (7.5%) patients in the ITG and 6 (11.5%) in the DTG had a 2 grade worsening of hemoglobin levels compared with baseline values. Similarly, mild, grade 1-2 elevations in INR occurred in approximately 27%-29% of patients in each treatment arm. INR > 1.5 3 baseline values were reported in 4 (3.7%) and 3 (5.8%) patients in the ITG and DTG, respectively. Grade 3-4 elevations in INR (2.1 3 upper limit of normal [ULN]) occurred in 1 patient receiving EBR/GZR and 3 receiving placebo. Grade 1-2 decline in platelet counts also occurred at a similar frequency in the ITG and DTG. Clinical events related to the underlying blood disorder were not apparent among those who received EBR/GZR compared to placebo treatment. There was no difference in the use of factor replacement therapy, sickle cell crises, or chelation events between treatment arms (see the Supporting Information for details).
Discussion
This is a randomized, phase III study to assess an alloral RBV-free treatment for HCV infection across a spectrum of patients with IBLD, including those with b- All values given as n (%). Three patients in the immediate-treatment group (ITG) reported a total of four serious AEs (sickle cell anemia with crisis, erosive gastritis, rectal hemorrhage, and hypophosphatemia). Six patients in the DTG reported a total of eight serious adverse events (sickle cell anemia with crisis [n 5 2], anemia, fall, increased ALT, increased AST, osteonecrosis, and chronic myeloid leukemia). One patient receiving placebo discontinued treatment because of an AE with increased ALT and AST. *AEs occurring in > 5% of patients receiving elbasvir/grazoprevir in the ITG. thalassemia or sickle cell disease. Administration of a 12associated hemolytic anemia. (3) Although RBV-induced anemia is reversible with discontinuation of the drug, additional blood transfusions can potentiate preexisting cardiac and hepatic dysfunction secondary to iron overload toxicity. Accordingly, the use of RBV in such patients requires careful monitoring and possibly an increase in chelation therapy. (3) In conclusion, EBR/GZR was safe and well tolerated when administered to patients with IBLDs and HCV infection. SVR12 rates were 93.5% in this study, indicating a high degree of efficacy. Overall, these data add to the expanding pool of data available for EBR/ GZR showing high efficacy and favorable tolerability in patients with HCV infection.
